Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 25.3738
- Book/Share 30.2066
- PB 3.8636
- Debt/Equity 0.289
- CurrentRatio 1.5759
- ROIC 0.0843
- MktCap 200657518571.0
- FreeCF/Share 4.233
- PFCF 27.1342
- PE 30.8724
- Debt/Assets 0.1738
- DivYield 0.0208
- ROE 0.1289
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | The Benchmark Company | -- | Buy | -- | $145 | Oct. 10, 2025 |
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich
Published: February 23, 2026 by: The Motley Fool
Sentiment: Positive
Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues.
Read More
Exact Sciences Stockholders Approve Acquisition by Abbott
Published: February 20, 2026 by: Business Wire
Sentiment: Neutral
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.
Read More
Abbott declares 409th consecutive quarterly dividend
Published: February 20, 2026 by: PRNewsWire
Sentiment: Neutral
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Read More
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla.
Read More
Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?
Published: February 12, 2026 by: 24/7 Wall Street
Sentiment: Positive
Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate.
Read More
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Published: February 04, 2026 by: Reuters
Sentiment: Negative
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Positive
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $20.8 billion in FY 2016 to $44.3 billion in FY 2025. That's a compound annual growth rate of 8.8%. Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.
Read More
10 Highest Rated Dividend Kings For Generations Of Income
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is The Fall In Abbott Stock Justified?
Published: January 23, 2026 by: Forbes
Sentiment: Neutral
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth.
Read More
Abbott Laboratories Raised Prices, Prompting Sales Slump
Published: January 22, 2026 by: WSJ
Sentiment: Negative
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Read More
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Published: January 22, 2026 by: Seeking Alpha
Sentiment: Neutral
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Read More
Jobless Claims Come in Slightly Higher
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative
Jobless Claims Come in Slightly Higher.
Read More
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
Published: January 22, 2026 by: Benzinga
Sentiment: Negative
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
Read More
Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.
Read More
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative
ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.
Read More
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Abbott (ABT) Matches Q4 Earnings Estimates
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago.
Read More
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
2 Healthcare Names That Could Get a Big Boost From Earnings
Published: January 20, 2026 by: MarketBeat
Sentiment: Positive
Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.
Read More
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
ABT heads into Q4 earnings with adult nutrition in focus, as Ensure and Glucerna launches are expected to support modest segment growth.
Read More
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Read More
Dividend King Abbott Shows Why 52 Consecutive Increases Weren't Luck With Strong Cash Flow Coverage
Published: January 15, 2026 by: 24/7 Wall Street
Sentiment: Positive
Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert Ford
- Employees 114000